Researchers identify COVID-19 proteins that cause blood vessel damage
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
List view / Grid view
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
A new artificial intelligence (AI) method has been created to uncover which proteins enable bacteria to infect human intestines.
Scientists have visualised the spatial and temporal distribution of neural stem cell activation in zebrafish models.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A study conducted on human pancreatic tumours transplanted in mice reveals promise for an effective therapy in the future, say researchers.
A study has used a proteomic method to uncover why some melanoma tumours do not respond to immunotherapy, which could improve treatments.
Researchers have revealed a key inflammation mechanism that contributes to melanoma brain metastasis and could be a therapeutic target.
A novel nano-vaccine has been developed which has proven effective in treating primary tumours and metastases that result from melanoma.
Researchers used screening to discover genes that protect the body against the Zika virus, which could inform potential therapies against the virus.
Researchers have found that fat cells transfer cytokines to melanoma cells, which transforms them into aggressive tumours, indicating a drug target for the condition.
High level of specific protein in tumours indicates prognosis as well as optimal treatments...
A study has shown that breast cancer uses stromal cells originally formed in bone marrow to boost their growth and metastasis of the cancer...
Scientists have uncovered a promising drug candidate that appears to normalise the vocal communication mechanism deficiencies experienced in genetic disorder ADNP.
A new Tel Aviv University study identifies a previously unknown mechanism involved in the development of Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS).